The first Russian intradermal implant has successfully passed the state registration. This product has been developed over the past three years with the support of the Russian Ministry of Industry and Trade.
In the future, once the enterprise reaches its production capacity, it will employ only local specialists from Penza. The program provides for gradual increase of production capacity over a two-year period.
NPO Microgen has begun phase 2 clinical trials of the first Russian polysaccharide meningococcal vaccine to prevent diseases caused by Neisseria meningitidis serogroups A and C, including meningitis and meningococcemia.